PFE Stock Analysis

Key Financial Metrics

📊Valuation

P/E Ratio
18.71
Forward P/E
16.04
P/S Ratio
1.29
P/B Ratio
5.35
EV/EBITDA
13.56
EV/Revenue
1.39
PEG Ratio
1.48

💰Profitability

Gross Margin
36.4%
Operating Margin
24.9%
Net Margin
18.5%
ROE
25.1%
ROA
8.6%
ROIC
16.0%

📈Growth

Revenue Growth (YoY)
5.7%
EPS Growth (YoY)
8.3%
FCF Growth
11.1%

🏦Financial Health

Debt/Equity
0.77
Current Ratio
1.42
Quick Ratio
1.14
Interest Coverage
12.47

💵Dividends

Dividend Yield
1.5%
Payout Ratio
29.9%
Dividend Growth
5.3%

📋Per Share

EPS
$26.31
Book Value/Share
$91.22
FCF/Share
$21.12
Revenue/Share
$94.74

Proprietary Model

Finlytics Score

Instant view of the current conviction score for PFE, with component-level transparency.

Refreshing score...Loading live inputs

Pro Feature

Peer Comparison

Compare valuation, growth, margins, and Finlytics Score against the closest sector names.

Previewing 2 peers

🔒 See full peer comparison with Pro — $29/month

Upgrade to Pro

Company overview

About Pfizer, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Finlytics combines this business profile with an interactive DCF valuation, bear/base/bull intrinsic value scenarios, financial statements, peer comparison, and the Finlytics Score so investors can evaluate PFE stock from multiple angles.

Finlytics Score
68/100
Trailing P/E
36.6
Revenue Growth
+2.6%
Market Cap
$158.4B

Price History

1Y Performance: -14.60%

Financial Statements

Reported fundamentals across filing periods

Revenue, margins, and earnings power across reported periods.

Positive changeNegative change

Annual filings

Loading statement history